title: [Anti-EGFR antibody therapy for colorectal cancer].
abstract: The epidermal growth factor receptor (EGFR) triggers a downstream signaling cascade such as the RAS-RAF-MAPK and PI3K-AKT pathways, which are involved in cell proliferation, differentiation, survival and invasion. Two monoclonal antibodies (moABS) targeting EGFR, cetuximab and panitumumab, are established to be a new treatment for metastatic colorectal cancers. Among activating mutations in the downstream of EGFR, the KRAS gene mutation has shown to be predictive biomarker for resistance to anti-EGFR antibody therapy. This review focuses on the current status of chemotherapy with anti-EGFR antibody for colorectal cancers. The identification of patients who are likely to benefit from EGFR-targeted moABS is increasingly crucial for improving therapeutic strategies.
authors.affiliation: Department of Surgical Oncology, Tokyo Medical and Dental University, Graduate School of Medicine and Dentistry.
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Ishikawa
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Uetake
authors.forename: Kenichi
authors.initials: K
authors.lastname: Sugihara
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D066246:ErbB Receptors / Q000276:immunology*; D006801:Humans; D009154:Mutation / Q000235:genetics; D011518:Proto-Oncogene Proteins / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; D066246:ErbB Receptors; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins